TCGA-AR-A2LN-01A-21R-A18M-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 39
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- UV_RESPONSE_DN+0.400
- ANGIOGENESIS+0.380
- HEDGEHOG_SIGNALING+0.380
- TGF_BETA_SIGNALING+0.380
- MYOGENESIS+0.370
- APICAL_SURFACE+0.350
- KRAS_SIGNALING_UP+0.350
- INFLAMMATORY_RESPONSE+0.340
Top 10 suppressed
- MYC_TARGETS_V1-0.690
- E2F_TARGETS-0.670
- MYC_TARGETS_V2-0.670
- OXIDATIVE_PHOSPHORYLATION-0.630
- G2M_CHECKPOINT-0.610
- MTORC1_SIGNALING-0.590
- DNA_REPAIR-0.530
- UNFOLDED_PROTEIN_RESPONSE-0.480
- PI3K_AKT_MTOR_SIGNALING-0.420
- GLYCOLYSIS-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LL-A440-01A-11R-A24H-07 | — | A | 0.953 |
| 2 | SRR35579834 | — | A | 0.946 |
| 3 | 20020074.LumA | — | A | 0.935 |
| 4 | TCGA-BH-A8G0-01A-11R-A352-07 | — | A | 0.928 |
| 5 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.926 |
| 6 | TCGA-BH-A0DP-01A-21R-A056-07 | — | A | 0.923 |
| 7 | MBCProject_3896_T1_RNA | — | A | 0.922 |
| 8 | TCGA-E2-A1IJ-01A-11R-A144-07 | — | A | 0.920 |
| 9 | SRR17866847 | — | — | 0.915 |
| 10 | TCGA-SY-A9G0-01A-12R-A38B-07 | — | — | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |